IS THERE A LINK BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND LUNG-CANCER SUSCEPTIBILITY

被引：15

作者：

HORSMANS, Y ^{[1
]}

DESAGER, JP ^{[1
]}

HARVENGT, C ^{[1
]}

机构：

[1] CATHOLIC UNIV LOUVAIN,PHARMACOTHERAPIE LAB,53 AVE E MOUNIER,B-1200 BRUSSELS,BELGIUM

来源：

BIOMEDICINE & PHARMACOTHERAPY | 1991年 / 45卷 / 08期

关键词：

LUNG CANCER; DEBRISOQUINE; PHENOTYPE;

D O I：

10.1016/0753-3322(91)90066-3

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

A link between debrisoquine oxidation phenotype and lung cancer susceptibility has been evoked by some authors but not confirmed by others. For this reason, we compared the frequency of debrisoquine poor metabolizer phenotype in 91 Belgian patients with lung cancer to that studied in 167 healthy Belgian subjects. No significant difference was observed in our study. These results do not support the existence of this link.

引用

页码：359 / 362

页数：4

共 14 条

[1] HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].

ALVAN, G ;

BECHTEL, P ;

ISELIUS, L ;

GUNDERTREMY, U .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537

[2] METABOLIC OXIDATION PHENOTYPES AS MARKERS FOR SUSCEPTIBILITY TO LUNG-CANCER [J].

AYESH, R ;

IDLE, JR ;

RITCHIE, JC ;

CROTHERS, MJ ;

HETZEL, MR .

NATURE, 1984, 312 (5990) :169-170

[3] DEBRISOQUINE OXIDATION PHENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER [J].

BOOBIS, AR ;

DAVIES, DS .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) :653-656

[4] CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].

BROSEN, K ;

GRAM, LF .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547

[5]

CAPORASO N, 1989, CANCER RES, V49, P3675

[6] LACK OF A RELATIONSHIP BETWEEN THE POLYMORPHISM OF DEBRISOQUINE OXIDATION AND LUNG-CANCER [J].

DUCHE, JC ;

JOANNE, C ;

BARRE, J ;

DECREMOUX, H ;

DALPHIN, JC ;

DEPIERRE, A ;

BROCHARD, P ;

TILLEMENT, JP ;

BECHTEL, P .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (05) :533-536

[7] A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION [J].

EVANS, DAP ;

MAHGOUB, A ;

SLOAN, TP ;

IDLE, JR ;

SMITH, RL .

JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) :102-105

[8] CHEMICAL CARCINOGENESIS [J].

FARBER, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (23) :1379-1389

[9] DEBRISOQUINE METABOLISM AND GENETIC PREDISPOSITION TO LUNG-CANCER [J].

LAW, MR ;

HETZEL, MR ;

IDLE, JR .

BRITISH JOURNAL OF CANCER, 1989, 59 (05) :686-687

[10] PREVALENCE OF DRUG HYDROXYLATOR PHENOTYPES IN BELGIUM [J].

LECLERCQ, V ;

DESAGER, JP ;

VANNIEUWENHUYZE, Y ;

HARVENGT, C .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 33 (04) :439-440

← 1 2 →